WO2014101458A1 - 化学改性的海丝纤维、由其制成的伤口敷料及其制备方法 - Google Patents
化学改性的海丝纤维、由其制成的伤口敷料及其制备方法 Download PDFInfo
- Publication number
- WO2014101458A1 WO2014101458A1 PCT/CN2013/082802 CN2013082802W WO2014101458A1 WO 2014101458 A1 WO2014101458 A1 WO 2014101458A1 CN 2013082802 W CN2013082802 W CN 2013082802W WO 2014101458 A1 WO2014101458 A1 WO 2014101458A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fiber
- sea silk
- chemically modified
- wound dressing
- cellulose
- Prior art date
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 199
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 229920002678 cellulose Polymers 0.000 claims abstract description 48
- 239000001913 cellulose Substances 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000006467 substitution reaction Methods 0.000 claims abstract description 6
- 241001474374 Blennius Species 0.000 claims description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- 239000002245 particle Substances 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 25
- 235000010443 alginic acid Nutrition 0.000 claims description 19
- 229920000615 alginic acid Polymers 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000006266 etherification reaction Methods 0.000 claims description 17
- 230000002378 acidificating effect Effects 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 15
- 238000009987 spinning Methods 0.000 claims description 14
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 13
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 13
- 229940072056 alginate Drugs 0.000 claims description 12
- 229920001661 Chitosan Polymers 0.000 claims description 10
- 235000010413 sodium alginate Nutrition 0.000 claims description 10
- 239000000661 sodium alginate Substances 0.000 claims description 10
- 229940005550 sodium alginate Drugs 0.000 claims description 10
- 229920003043 Cellulose fiber Polymers 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 239000000783 alginic acid Substances 0.000 claims description 7
- 229960001126 alginic acid Drugs 0.000 claims description 7
- 150000004781 alginic acids Chemical class 0.000 claims description 7
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 claims description 7
- 229920000297 Rayon Polymers 0.000 claims description 6
- 210000000416 exudates and transudate Anatomy 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920000433 Lyocell Polymers 0.000 claims description 4
- 241000199919 Phaeophyceae Species 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000008935 nutritious Nutrition 0.000 claims description 4
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229920003064 carboxyethyl cellulose Polymers 0.000 claims description 3
- 239000003925 fat Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 2
- 229920002413 Polyhexanide Polymers 0.000 claims description 2
- 241000206572 Rhodophyta Species 0.000 claims description 2
- 229920002978 Vinylon Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 235000010410 calcium alginate Nutrition 0.000 claims description 2
- 239000000648 calcium alginate Substances 0.000 claims description 2
- 229960002681 calcium alginate Drugs 0.000 claims description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical group [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 238000002166 wet spinning Methods 0.000 claims description 2
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims 1
- 238000000578 dry spinning Methods 0.000 claims 1
- 238000009940 knitting Methods 0.000 claims 1
- 150000003378 silver Chemical class 0.000 claims 1
- 238000009941 weaving Methods 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 52
- 208000027418 Wounds and injury Diseases 0.000 abstract description 52
- 230000029663 wound healing Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 241000195493 Cryptophyta Species 0.000 abstract description 2
- 238000007385 chemical modification Methods 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 40
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 24
- 239000004745 nonwoven fabric Substances 0.000 description 13
- 229910001961 silver nitrate Inorganic materials 0.000 description 12
- 229910052709 silver Inorganic materials 0.000 description 11
- 239000004332 silver Substances 0.000 description 11
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 9
- 239000002131 composite material Substances 0.000 description 9
- 229920002749 Bacterial cellulose Polymers 0.000 description 6
- 239000005016 bacterial cellulose Substances 0.000 description 6
- 238000001879 gelation Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000004080 punching Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- -1 carboxyethyl Chemical group 0.000 description 2
- 238000009960 carding Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 2
- 238000001891 gel spinning Methods 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011858 nanopowder Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000012991 xanthate Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01012—Non-adhesive bandages or dressings characterised by the material being made of natural material, e.g. cellulose-, protein-, collagen-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01034—Non-adhesive bandages or dressings characterised by a property
- A61F13/01042—Absorbency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01C—CHEMICAL OR BIOLOGICAL TREATMENT OF NATURAL FILAMENTARY OR FIBROUS MATERIAL TO OBTAIN FILAMENTS OR FIBRES FOR SPINNING; CARBONISING RAGS TO RECOVER ANIMAL FIBRES
- D01C3/00—Treatment of animal material, e.g. chemical scouring of wool
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/32—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with oxygen, ozone, ozonides, oxides, hydroxides or percompounds; Salts derived from anions with an amphoteric element-oxygen bond
- D06M11/36—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with oxygen, ozone, ozonides, oxides, hydroxides or percompounds; Salts derived from anions with an amphoteric element-oxygen bond with oxides, hydroxides or mixed oxides; with salts derived from anions with an amphoteric element-oxygen bond
- D06M11/38—Oxides or hydroxides of elements of Groups 1 or 11 of the Periodic Table
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/10—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing oxygen
- D06M13/184—Carboxylic acids; Anhydrides, halides or salts thereof
- D06M13/207—Substituted carboxylic acids, e.g. by hydroxy or keto groups; Anhydrides, halides or salts thereof
- D06M13/21—Halogenated carboxylic acids; Anhydrides, halides or salts thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/0017—Wound bandages possibility of applying fluid
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M2101/00—Chemical constitution of the fibres, threads, yarns, fabrics or fibrous goods made from such materials, to be treated
- D06M2101/02—Natural fibres, other than mineral fibres
- D06M2101/04—Vegetal fibres
- D06M2101/06—Vegetal fibres cellulosic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2927—Rod, strand, filament or fiber including structurally defined particulate matter
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2913—Rod, strand, filament or fiber
- Y10T428/2929—Bicomponent, conjugate, composite or collateral fibers or filaments [i.e., coextruded sheath-core or side-by-side type]
Definitions
- the present invention relates to chemically modified sea silk fibers (seacdl), wound dressings made therefrom, and methods of making same. Background technique
- a warm, moist wound environment facilitates wound healing and prevents tissue dehydration and cell death, and this environment also facilitates the interaction between cytokines and cells involved in wound healing.
- the modified cellulose with carboxymethylation or carboxyethylation has strong hygroscopicity and gelation property, can absorb liquid up to 15 times its own weight, and can absorb a liquid to form a moist environment, which is beneficial to wounds.
- colloidal substances can seal the wound, forming a relatively independent environment on the surface of the wound, preventing the intrusion of harmful substances around the body.
- the pressure generated can also promote the circulation of blood around the wound, which is conducive to supplementing nutrients and removing waste.
- the seaweed fiber is a new type of health and medical fiber made of cellulose and seaweed. It is a kind of regenerated cellulose fiber. Its main component is seaweed and cellulose, which is one of the seaweed fibers.
- the seaweed fiber is jointly developed by the cellulose technology. It is a fiber developed by utilizing the advantages of carbohydrates, proteins, amino acids, fats, cellulose and rich minerals contained in seaweed. Based on the production of Lyocell fiber, the finely ground seaweed powder or suspension is added to the spinning solution to be drawn: firstly, the seaweed powder is made into fine particles with a particle size of less than 9 microns.
- the seaweed fiber has a distinct lateral orientation, the orientation of the crystal zone is low, and the cross section exhibits a porous structure.
- the detection of the activity of the seaweed fiber proves that the active ingredient of the seaweed is not destroyed during the fiber making process and is combined with the porous fiber matrix.
- seaweed is added to the cellulose spinning solution. Since the seaweed fiber has alginic acid molecules in seaweed, it is rich in carboxylic acid groups and can be strongly combined with metal ions. In addition, seaweed plants contain many compounds related to life activities. Minerals in seaweed can effectively promote skin regeneration, keep skin fresh, firm and smooth; some ingredients have certain resistance The action of bacteria can be used to treat skin diseases; the carotene contained in seaweed is a raw material for the synthesis of vitamin A, which plays an important role in the health of the skin. When used, the active substance of seaweed in the seaweed fiber is slowly released from the fiber in a wet environment, and has a health and health effect on the skin.
- Chinese patent CN 101967698 A discloses a preparation method of alginate/cellulose composite fiber, which comprises the following steps: (1) alkalizing cellulose pulp by alkalization with NaOH solution to obtain alkali cellulose. (2) Sodium alginate is added to the alkali cellulose in an amount of 1 to 5 wt% of the alkali cellulose, and the mixture is uniformly mixed. (3) A yellowing reaction was carried out by adding 8 2 to the above mixture, and dissolved in deionized water to prepare a cellulose/alginate xanthate viscose. (4) The cellulose/alginate xanthate viscose is filtered, defoamed, and matured to obtain a viscose spinning dope. (5) The viscose spinning dope is wet-spun and solidified into a composite fiber containing cellulose and alginate. (6) The composite fiber is plasticized and drawn in a plasticating bath to obtain a finished alginate/cellulose composite fiber.
- Chinese patent CN 101613893A discloses a bacterial cellulose/alginate composite fiber and a preparation method thereof, the sodium alginate nanopowder is added to a bacterial cellulose solution and uniformly dispersed by ultrasonic waves, and then the bacterial fiber is obtained by wet spinning. And sodium alginate composite fiber; wherein, the content of sodium alginate in the composite fiber is 5% to 20%, and the content of bacterial cellulose in the composite fiber is 80% to 95%.
- the preparation method comprises: dissolving an appropriate amount of bacterial cellulose in an imidazolium chloride salt ionic liquid to obtain a bacterial cellulose solution having a mass percentage concentration of 5 to 10%; and then adding a certain amount of sodium alginate micro-nano powder, uniformly dispersed And defoaming, to obtain a spinning dope; the spinning dope is extruded into a coagulation bath through a spinneret, and after stretching and drying, a composite fiber of bacterial cellulose and sodium alginate is obtained.
- Chinese patent CN101 168869A discloses a soy protein/alginate/cellulose fiber and a preparation method thereof, which is a spinning solution prepared by using a soy protein solution, an alginate solution and a high-viscosity cellulose solution, and adopting a multi-stage coagulation bath.
- the components are separately molded to obtain fibers having a soy protein content of 15 to 60% by weight, an alginate content of 3 to 8% by weight, and a cellulose content of 32 to 82% by weight.
- the above prior art has the disadvantage that the sodium alginate powder has a large particle size and cannot be uniformly and stably dispersed in the structure of the cellulose component during the mixing with the cellulose spinning solution, except that the original fiber is retained.
- the characteristic is that sodium alginate and cellulose are independent of each other and do not interact to exert a nutrition and anti-infection barrier; in addition, the gel prepared and hygroscopicity of the fibers prepared by the prior art are not ideal, which is not conducive to wound healing. Summary of the invention
- the present invention provides a chemically modified sea silk fiber, which is made of the same a wound dressing and a preparation method thereof, wherein a modified cellulose is obtained by chemically modifying a seaweed fiber into a water-absorbing group (for example, a carboxymethyl group or a carboxyethyl group) to form a modified cellulose.
- Silk fiber not only has hygroscopicity and gelation, it provides a moist environment for wound healing, but also retains the active ingredients of seaweed particles in the original seaweed fiber, and slowly releases the active ingredient in a humid environment to support wound healing.
- One aspect of the invention relates to a chemically modified sea silk fiber, characterized in that a cellulose component in the sea silk fiber is chemically modified to introduce a water-absorbing group to be converted into a modified cellulose component,
- the degree of substitution of the modified cellulose component is from 0.05 to 0.5, preferably from 0.2 to 0.4, and the linear density of the seaweed fiber is from 0.5 to 5 dtex, preferably from 1 to 4 dtex, and the fiber length is from 5 to 180 mm, preferably from 15 to 125 mm.
- the chemically modified sea silk fiber of the present invention wherein the sea silk fiber is prepared by adding seaweed particles to a cellulose spinning solution, followed by dry-wet spinning or solvent spinning.
- the chemically modified sea silk fiber of the present invention wherein the seaweed particles have a particle diameter of from 1 to 100 ⁇ m, preferably from 1 to 50 ⁇ m.
- the chemically modified sea silk fiber of the present invention wherein the seaweed particles are selected from the group consisting of red algae particles, brown algae particles, and brown algae particles.
- the chemically modified sea silk fiber of the present invention wherein the seaweed particles are uniformly and stably distributed in the structure of the modified cellulose component.
- the chemically modified sea silk fiber of the present invention wherein the modified cellulose component is selected from the group consisting of carboxymethyl cellulose fibers or carboxyethyl cellulose fibers.
- the chemically modified sea silk fiber of the present invention wherein the modified cellulose component absorbs the exudate to form a moist gel, so that the active ingredient of the seaweed particle is slowly released, thereby providing moistness to the wound and A nutritious healing environment.
- the chemically modified sea silk fiber of the present invention wherein the active ingredient of the seaweed particle is selected from the group consisting of alginic acid, carbohydrates, amino acids, minerals, fats and vitamins.
- the chemically modified sea silk fiber of the present invention wherein the alginic acid is selected from the group consisting of a high mannuronic acid type or a high guluronic acid type or a mannuronic acid/guluronic acid mixed type.
- Another aspect of the invention relates to a wound dressing prepared from the above chemically modified sea silk fiber, the wound dressing being selected from a wound dressing prepared entirely from the chemically modified sea silk fiber or modified by the chemical A wound dressing prepared by blending a seaweed fiber with other fibers.
- the wound dressing of the present invention can absorb the hydrazine solution up to 12 g/100 cm 2 or more, wherein the A solution means that 8.89 g of sodium chloride and 0.368 g of anhydrous calcium chloride are dissolved in 1 L of pure water.
- the wound dressing of the present invention can have a wet strength of 0.3 N/cm or more. Since the wound dressing absorbs the wound exudate or the A solution and forms a gel, the material becomes a gel and becomes quite fragile and heavy, which causes some difficulties in measuring the wet strength of the dressing by the tensile testing machine. If the force of the clamp gripping the sample is too large, the sample is often crushed by the clamp. If the force of the gripping sample is too small, the sample will often slip in the fixture. To do this, only the middle portion of the sample is wetted, while the ends of the sample are kept dry, and the dry portion can be clamped by the tester.
- the general procedure for measuring the wet strength of a dressing is as follows:
- the second specimen is preferably cut at an angle of 90 degrees to the first specimen to ensure simultaneous MD (longitudinal) and CD (lateral) orientation.
- the distance between the two jaws is 50 mm, and the running speed of the top jaw is set to 100 mm/min.
- N the maximum force (N) of the damaged sample. It is recommended that two samples from the same dressing (10 x 10 cm) be tested at the same time so that the measured strength value can be recorded as CD and the other intensity value can be recorded as MD.
- the wound dressing of the present invention may be prepared by blending modified sea silk fibers with other fibers, and the other fibers may be selected from the group consisting of sea silk fibers, cellulose fibers, modified cellulose fibers, preferably carboxymethyl cellulose fibers or carboxy groups.
- the ethyl cellulose fiber and the alginate fiber are preferably calcium alginate fiber or sodium alginate fiber, chitosan fiber, modified chitosan fiber, preferably acylated chitosan fiber or carboxymethyl chitosan fiber, Lai Xaar, viscose, nylon, vinylon and polyester.
- the wound dressing of the present invention may further contain an antibacterial agent such as a silver salt, a nanosilver and a polyhexamethylene biguanide.
- an antibacterial agent such as a silver salt, a nanosilver and a polyhexamethylene biguanide.
- the wound dressing of the present invention can be prepared by a woven, knitted or non-woven process. Still another aspect of the invention relates to a method of preparing the above chemically modified sea silk fiber, comprising the steps of:
- the seaweed fiber in a 10% by weight to 50% by weight sodium hydroxide solution at room temperature, wherein the volume ratio of the sea silk fiber to the sodium hydroxide solution is 1:7 to 1 : 10; 2) taking out the fiber obtained in 1) and squeezing it out, and then performing an etherification reaction with the etherification liquid for 10 to 120 minutes, the etherification liquid being a solution composed of sodium chloroacetate, sodium hydroxide, water and ethanol. Wherein the concentration of sodium chloroacetate is 18-50% by weight based on the total weight of the etherified liquid;
- the etherification reaction involved in step 2) of the process of the invention is carried out as follows: The etherification liquid is first preheated to 30-50 ° C, then the fiber obtained in step 1) is added and heated, to be the ether The cycle cooling was started when the temperature of the chemical reached 40-65 ° C, and the temperature of the etherification liquid was maintained at 45-60 ° C until the fibers were gelatinized.
- the present invention makes the jelly fiber have hygroscopicity and gelation property through a one-step modification process, and retains the active component of the seaweed particles, thereby providing a moist and nutritious healing environment for the wound, and improving the application effect of the seaweed fiber. Expanded the scope of application.
- the sol-like fiber comes into contact with the wound, absorbing the wound secretion, and forming a moist and warm environment, which is favorable for wound healing.
- the seaweed fiber is blended with seaweed particles in the spinning solution of cellulose, the sea silk fiber not only combines the strength and flexibility of the regenerated cellulose fiber by the solvent method, but also retains the biological activity of the seaweed particles. Has a bacteriostatic effect.
- the invention adopts chemical modification of cellulose therein to introduce a water-absorbing group (for example, carboxymethyl or carboxyethyl) to make the jelly fiber have water absorption and gelation property, and is used for moderate to severe exudate.
- the wound absorbs the wound exudate to provide a moist environment for the wound; in addition, the algae acid of the seaweed granules not only provides hygroscopicity and gelation, but also provides nutrient and antibacterial protection for wound healing.
- the active ingredients of the seaweed particles can be slowly released, which is beneficial to the healing of the wound.
- the modified sea silk fiber of the invention not only has the hygroscopicity and gelation property of the modified cellulose, but also retains the active ingredient of the seaweed particles, thereby providing a moist and nutritious healing environment for the wound and enhancing the seaweed fiber.
- the degree of substitution of the modified sea filament fiber obtained by the above method was 0.29.
- the obtained modified sea silk fiber is cut and a short fiber having a linear density of 3 dtex and a fiber length of 50 mm is obtained, and then the modified sea silk fiber nonwoven fabric is obtained by a conventional non-woven fabric thread; after being divided, cut, Packaging and sterilizing a modified seaweed fiber wound dressing of a certain size.
- the wound dressing had an absorption of 19 g/100 cm 2 and a wet strength of 0.35 N/cm.
- the degree of substitution of the modified sea silk fiber obtained by the above method was 0.28.
- the obtained modified sea silk fiber is cut and a short fiber having a linear density of 4 dtex and a fiber length of 60 mm is obtained, and then the modified sea silk fiber nonwoven fabric is obtained by using a conventional non-woven fabric thread; and then divided, cut, and packaged. And after sterilization, a certain modified seaweed fiber wound dressing is prepared.
- the wound dressing had an absorption of 19.5 g/100 cm 2 and a wet strength of 0.40 N/cm.
- the degree of substitution of the modified sea filament fiber obtained by the above method was 0.30.
- the obtained modified sea silk fiber is cut and a staple fiber having a linear density of 5 dtex and a fiber length of 55 mm is obtained, and then the modified sea silk fiber nonwoven fabric is obtained by using a conventional non-woven fabric thread; and then divided, cut, packaged, and After sterilization, a modified seaweed fiber wound dressing of a certain specification is prepared.
- the wound dressing had an absorption of 21 g/100 cm 2 and a wet strength of 0.35 N/cm.
- the modified sea-fiber staple fiber obtained by the method of Example 1 having a linear density of 4 dtex and a length of 55 mm was blended with the modified cellulose developed by Foshan Youte Medical Technology Co., Ltd. After opening, combing, laying and two needle punching, a non-woven fabric is obtained, which is then divided, cut, packaged and sterilized to make a certain size of wound dressing.
- the wound dressing absorbs 19g/100cm 2 .
- the wet strength was 0.38 N/cm.
- the modified seaweed staple fiber obtained by the method of Example 1 having a linear density of 4 dtex and a length of 55 mm was blended with the acylated chitosan fiber purchased from the instant group, and subjected to opening, carding, laying and two After the secondary needling, a non-woven fabric is obtained, which is then divided, cut, packaged and sterilized to prepare a wound dressing of a certain specification.
- the wound dressing has an absorption capacity of 15 g/100 cm 2 and a wet strength of 0.50 N/cm.
- the modified seaweed staple fiber obtained by the method of Example 2 having a linear density of 3 dtex and a length of 55 mm is blended with the M-type alginic acid fiber developed by Foshan Youte Medical Technology Co., Ltd., and is opened, carded, and laid. After the netting and two needle punching, the non-woven fabric is prepared, and then divided, cut, packaged and sterilized to make a certain size wound dressing.
- the wound dressing absorbs 14g/100cm 2 and the wet strength is 1.30N. /cm.
- the modified seaweed staple fiber obtained by the method of Example 2 having a linear density of 3 dtex and a length of 55 mm was blended with the M/G type alginic acid fiber developed by Foshan Youte Medical Technology Co., Ltd., and opened and combed. After laying the net and two needles, the non-woven fabric is obtained, and then divided, cut, packaged and sterilized to make a certain size wound dressing.
- the wound dressing absorbs 16g/100cm 2 and the wet strength is 1.60 N/cm.
- the polysaccharide fiber is blended, and the non-woven fabric is obtained by opening, carding, laying and two needle punching, and then dividing, cutting, packaging and sterilizing to prepare a certain size wound dressing, the wound dressing
- the absorption was 21 g/100 cm 2 and the wet strength was 0.85 N/cm.
- the silver-containing modified sea silk fiber obtained by the above method had a silver content of 1.2%.
- the silver-containing modified sea silk fiber obtained by the above method has a silver content of 1.0%.
- the silver-containing modified sea silk fiber staple fiber obtained by the method of Example 10 and having a linear density of 2 dtex and a length of 55 mm was blended with the M/G type alginate fiber developed by Foshan Youte Medical Technology Co., Ltd. After combing, laying and two needles, the non-woven fabric is prepared, and then divided, cut, packaged and sterilized to make a certain size of wound dressing.
- the wound dressing absorbs 14g/100cm 2 , wet The strength is 1.45 N/cm.
- the silver-containing modified sea silk fiber staple fiber having a linear density of 2 dtex and a length of 60 mm obtained by the method of Example 10 was blended with the silver-containing chitosan fiber purchased from the instant group, and opened, carded, After laying the net and two needles, the non-woven fabric is prepared, and then divided, cut, packaged and sterilized to make a certain size wound dressing.
- the wound dressing absorbs 17g/100cm 2 and the wet strength is 1.0. N/cm.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Textile Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Artificial Filaments (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Abstract
本发明涉及化学改性的海丝纤维、由其制成的伤口敷料及其制备方法,所述化学改性的海丝纤维的特征在于,所述海丝纤维中的纤维素成分经过化学改性引入吸水性基团而转变成改性纤维素成分,所述改性纤维素成分的取代度为0.05-0.5,所述海丝纤维的线密度是0.5-5dtex,纤维长度是5-180mm。本发明通过一步改性工艺使海丝纤维具有吸湿性和成胶性,而且保留海藻颗粒的活性成分,从而可以为伤口提供湿润和营养的愈合环境,增强了海丝纤维的应用效果,扩大了应用范围。
Description
化学改性的海丝纤维、 由其制成的伤口敷料及其制备方法 技术领域
本发明涉及化学改性的海丝纤维 (seacdl) 、 由其制成的伤口敷料及其 制备方法。 背景技术
温暖、潮湿的创伤环境有利于伤口痊愈而且防止组织的脱水和细胞的死 亡,而且这种环境也有利于在伤口愈合过程中涉及到的细胞因子和细胞之间 的相互作用。 羧甲基化或羧乙基化的改性纤维素具有很强的吸湿性和成胶 性, 可以吸收高达其自身重量 15倍以上的液体, 并且吸收液体后可以形成 湿润的环境, 有利于伤口的愈合和清创。 另外胶体状的物质可以封闭伤口, 使伤口表面形成一个相对独立的环境, 阻止周围有害物质的侵入, 所产生的 压力还可以促进伤口周围血液的流通, 有利于补充营养物质和清除废弃物。
海丝纤维是用纤维素和海藻制成的新型保健和医疗专用纤维, 是一种再 生纤维素纤维, 其主要成分是海藻和纤维素, 属于海藻纤维中的一种。 海丝 纤维是采用纤维素工艺共同开发研制而成, 是利用海藻内含有的碳水化合 物、 蛋白质、 氨基酸、 脂肪、 纤维素和丰富矿物质的优点所开发出的纤维, 这种纤维的制法是以莱赛尔 (Lyocell)纤维的生产制造为基础, 在纺丝溶液 中加入研磨得很细的海藻粉末或悬浮物予以抽丝而成:首先将海藻粉末制成 粒径小于 9微米的微细颗粒, 将其粉末加在纤维素的 NMMO溶液中, 或在 纤维素溶解前加入, 形成由纤维素、 海藻、 NMMO和水组成的分散纺丝液, 通过干湿法紡丝加工制得海丝纤维。其强度与普通莱赛尔纤维相近, 具有较 好的可纺性。 采用电镜分析, 海丝纤维具有明显的横向取向, 晶区取向低, 截面呈现多孔性结构。 对海丝纤维活性检测, 证明海藻的活性成分在纤维制 造过程中没有被破坏, 并与多孔纤维基体结合。 当使用海丝纤维时, 海藻的 活性物质在湿环境中会从纤维中慢慢释放出来, 对皮肤具有健康保健作用。
与莱赛尔相比, 在纤维素紡丝液中加入了海藻, 由于海丝纤维中有海藻 中的海藻酸分子, 它富含有羧酸基团, 可以和金属离子牢固结合。 此外, 海 藻类植物所包含的成分多为与生命活动有关的化合物,海藻中的矿物质可有 效地促进皮肤再生, 使皮肤保持新鲜、 结实、 光滑; 一些成分还有一定的抗
菌作用, 可以用来治疗皮肤病;海藻中含有的胡萝卜素是合成维生素 A的原 料, 对皮肤的健康有很重要的作用。 使用时, 海丝纤维中海藻的活性物质在 湿环境中会从纤维中慢慢释放出来, 对皮肤具有健康保健作用。
中国专利 CN 101967698 A公开了一种海藻酸盐 /纤维素复合纤维的制备 方法, 包括如下歩骤: (1 ) 将纤维素浆粕经 NaOH溶液浸渍碱化得到碱纤 维素。 (2) 将海藻酸钠按碱纤维素的 l〜5wt%加入碱纤维素中, 混合均匀。 (3 ) 在上述混合物中加入 82进行黄化反应, 加入去离子水溶解, 制备成 纤维素 /海藻酸黄原酸酯粘胶。 (4) 将纤维素 /海藻酸黄原酸酯粘胶经过滤、 脱泡、 熟成后得到粘胶纺丝原液。 (5 ) 将粘胶纺丝原液经湿纺成型, 凝固 再生为含有纤维素和海藻酸盐的复合纤维。 (6 ) 将复合纤维在塑化浴中经 塑化、 牵伸得到成品海藻酸盐 /纤维素复合纤维。
中国专利 CN 101613893A公开了一种细菌纤维素 /海藻酸钠复合纤维及 其制备方法,将海藻酸钠纳米粉体添加到细菌纤维素溶液中并用超声波分散 均匀, 然后通过湿法紡丝获得细菌纤维素与海藻酸钠复合纤维; 其中, 海藻 酸钠在复合纤维中的含量为 5%~20%, 细菌纤维素在复合纤维中的含量为 80%〜95%。制备方法包括:将适量的细菌纤维素溶解于咪唑基氯盐离子液体 中, 得到质量百分比浓度为 5~10%的细菌纤维素溶液; 然后加入一定量的海 藻酸钠微纳米粉体, 分散均匀并脱泡, 得到纺丝原液; 将纺丝原液经喷丝头 挤入到凝固浴中, 拉伸及烘干后得到细菌纤维素与海藻酸钠复合纤维。
中国专利 CN101 168869A公开了一种大豆蛋白 /海藻酸盐 /纤维素纤维及 其制备方法, 为采用大豆蛋白溶液、 海藻酸盐溶液与高粘度纤维素溶液制得 纺丝原液,采用多级凝固浴使各种组分分别成型,得到大豆蛋白含量为 15~60 重量%, 海藻酸盐含量为 3~8重量%, 纤维素含量为 32〜82重量%的纤维。
但是, 上述现有技术的缺点在于海藻钠粉体粒径较大, 在与纤维素纺丝 液混合过程中并不能均匀并稳定地分散于纤维素成分的结构中,只是各自保 留原有纤维的特点, 即海藻酸钠与纤维素是相互独立的, 并没有相互作用而 发挥营养和抗感染屏障; 此外, 现有技术制备的纤维的成胶性和吸湿性不够 理想, 不利于伤口的愈合。 发明内容
为了克服上述缺点, 本发明提供一种化学改性的海丝纤维、 由其制成的
伤口敷料及其制备方法, 其中通过对海丝纤维进行化学改性, 使其中的纤维 素引入吸水性基团 (例如羧甲基或羧乙基)而成为改性纤维素, 这种改性海 丝纤维不但具有吸湿性和成胶性, 为伤口愈合提供湿润的环境, 而且还保留 了原始海丝纤维中海藻颗粒的活性成分, 在湿润环境中缓慢释出活性成分, 为伤口愈合提供支持。
本发明的一个方面涉及一种化学改性的海丝纤维, 其特征在于, 所述海 丝纤维中的纤维素成分经过化学改性引入吸水性基团而转变成改性纤维素 成分, 所述改性纤维素成分的取代度为 0.05-0.5, 优选 0.2-0.4, 所述海丝纤 维的线密度是 0.5-5dtex,优选 l-4dtex,纤维长度是 5-180mm,优选 15-125mm。
本发明的化学改性的海丝纤维,其中所述的海丝纤维是通过在纤维素纺 丝液中加入海藻颗粒, 然后经过干湿法纺丝或溶剂纺丝制备而成。
本发明的化学改性的海丝纤维,其中所述的海藻颗粒的粒径是 1-100μηι, 优选 1-50μηι。
本发明的化学改性的海丝纤维, 其中所述的海藻颗粒选自红藻颗粒、 褐 藻颗粒和棕藻颗粒。
本发明的化学改性的海丝纤维,其中所述的海藻颗粒均匀且稳定地分布 于所述改性纤维素成分的结构中。
本发明的化学改性的海丝纤维,其中所述的改性纤维素成分选自羧甲基 纤维素纤维或羧乙基纤维素纤维。
本发明的化学改性的海丝纤维,其中所述的改性纤维素成分吸收渗出液 后形成湿润的凝胶, 使得所述海藻颗粒的活性成分缓慢地释出, 从而为伤口 提供湿润和营养的愈合环境。
本发明的化学改性的海丝纤维,其中所述的海藻颗粒的活性成分选自海 藻酸、 碳水化合物、 氨基酸、 矿物质、 脂肪和维生素。
本发明的化学改性的海丝纤维,其中所述的海藻酸选自高甘露糖醛酸型 或高古洛糖醛酸型或甘露糖醛酸 /古洛糖醛酸混合型。
本发明的另一个方面涉及一种由上述化学改性的海丝纤维制备的伤口 敷料,所述伤口敷料选自全部由所述化学改性的海丝纤维制备的伤口敷料或 由所述化学改性的海丝纤维与其他纤维混纺制备的伤口敷料。
本发明的伤口敷料, 其对 Α溶液的吸收量可以达到 12g/100cm2以上, 其中 A溶液是指 1L纯水中溶有 8.289g氯化钠和 0.368g无水氯化钙。
本发明的伤口敷料, 其湿强度可以达到 0.3N/cm或以上。 由于此种伤口 敷料吸收伤口渗出液或者 A溶液后会形成凝胶,材质会变成胶体从而变得相 当脆弱和沉重, 在用拉力试验机测量敷料湿强度时会带来一些困难。 如果夹 具紧握样品的力量过大, 样品往往会被夹具粉碎。 如果夹具抓握样品的力量 过小, 样品常会在夹具中出现滑动。 为此只湿润样品的中间部分, 而保持干 燥的样品两端, 而干燥部分可以由测试仪钳紧。 测量敷料湿强度的通用程序 如下:
1 ) 将样本切成 2厘米宽的长条试样, 长度必须至少为 7厘米。 一块 10 X 10 cm的伤口敷料,最好在与第一块试样成角 90度的方向上剪裁下第二 块试样, 以保证同时获得 MD (纵向) 和 CD (横向) 方向的样品。
2 ) 对折试样, 将对折的中间部分置于测试液中, 关于测试液, 推荐 使用 BP1995中规定的 A溶液, 静置 30秒。
3 ) 将试样夹出容器, 将其两端放入拉伸试验机夹具的顶部和底部。
4) 两钳口距离为 50 mm, 并把顶钳口的运行速度设为 100 mm/min。
5 ) 记录破坏样品的最大用力(N)。建议在同一时间对来源于同一敷 料 (10 x 10 cm) 的两条试样进行测试, 这样, 测试出来的较髙强度值可记 为 CD , 而另一个强度值可记为 MD。
6) 另外, 还建议至少测试 5片敷料(5 个 MD和 5 个 CD湿强度), 以获得可靠的湿强度结果。 取其平均值为此伤口敷料的湿强度值。
本发明的伤口敷料, 可以由改性海丝纤维与其他纤维混纺而制得, 所述 其他纤维可以选自海丝纤维、 纤维素纤维、 改性纤维素纤维优选羧甲基纤维 素纤维或羧乙基纤维素纤维、海藻酸盐纤维优选海藻酸钙纤维或海藻酸钙钠 纤维、 壳聚糖纤维、 改性壳聚糖纤维优选酰化壳聚糖纤维或羧甲基壳聚糖纤 维、 莱赛尔纤维、 黏胶纤维、 锦纶纤维、 维纶纤维和涤纶纤维。
本发明的伤口敷料, 还可以含有抗菌剂, 例如银盐、 纳米银和聚六亚甲 基双胍。
本发明的伤口敷料, 可以通过机织、 针织或非织造工艺制备而成。 本发明的又一个方面涉及一种制备上述化学改性的海丝纤维的方法,包 括如下步骤:
1 )在室温下在 10重量%-50重量%的氢氧化钠溶液中充分浸泡和打散海 丝纤维, 其中所述海丝纤维和所述氢氧化钠溶液的体积比为 1 :7至 1 : 10;
2)把 1 )中得到的纤维取出并挤干, 然后与醚化液进行醚化反应 10-120 分钟, 所述醚化液为由氯乙酸钠、 氢氧化钠、 水和乙醇组成的溶液, 其中氯 乙酸钠的浓度以醚化液的总重量计为 18-50重量%;
3 )取出 2)中得到的纤维并使用酸性洗涤液洗涤两次, 然后使用浓度为 0.1-5重量%的吐温 20的无水乙醇溶液洗涤, 所述酸性洗涤液包含以酸性洗 涤液总重量计 0.5-5重量%的醋酸, 20-60重量%的水和 35-79.5重量%的乙醇, 且所述酸性洗涤液与所述纤维的质量比为 5: 1至 50:1 ;
4)将 3 ) 中得到的纤维在 30-80°C的温度下风干 10-60分钟, 得到化学 改性的海丝纤维。
本发明的方法中步骤 2 ) 所涉及的醚化反应按如下进行: 先把所述醚化 液预热至 30-50°C, 然后加入步骤 1 ) 中得到的纤维并加热, 待所述醚化液 的温度达到 40-65°C时开始循环冷却, 使所述醚化液的温度维持在 45-60°C 直至纤维成胶。
因此, 本发明通过一步改性工艺使海丝纤维具有吸湿性和成胶性, 而且 保留海藻颗粒的活性成分, 从而可以为伤口提供湿润和营养的愈合环境, 改 善了海丝纤维的应用效果, 扩大了应用范围。
当根据本发明的伤口敷料被用于护理溃疡性伤口时,溶胶性纤维与伤口 接触, 吸收伤口分泌液, 形成湿润而温暖的环境, 有利于伤口愈合。 由于海 丝纤维是在纤维素的纺丝液中加入海藻颗粒混纺而成,这种海丝纤维不仅结 合了溶剂法生产再生纤维素纤维的强度和柔性,而且还保留了海藻颗粒的生 物活性, 具有抑菌作用。 本发明通过对其中的纤维素进行化学改性, 引入吸 水性基团 (例如羧甲基或羧乙基) , 使海丝纤维具有吸水性和成胶性, 用于 中度至重度渗出液的伤口, 吸收伤口渗出液, 为伤口提供湿润环境; 另外, 海藻颗粒的海藻酸除了可以发挥吸湿性和成胶性的特点之外, 同时为伤口的 愈合提供营养和抗菌保护, 在改性纤维素吸收渗出液之后形成的湿润环境 中, 海藻颗粒的活性成分可以缓慢释出, 有利于伤口的愈合。
更重要的是, 在海丝纤维的纤维素纤维引入吸水性基团的过程中, 并没 有引起海藻颗粒性能上的变化, 海藻颗粒依然可以均匀分布于改性纤维素 中。 因此, 本发明的改性海丝纤维不但具备改性纤维素的吸湿性和成胶性, 而且保留了海藻颗粒的活性成分,从而可以为伤口提供湿润和营养的愈合环 境, 增强了海丝纤维的应用效果, 扩大了应用范围。
具体实施方式
实施例 1
( 1 ) 在室温下, 将 200g购自 smartfiber的商标名为 seacel的海丝纤维 用 1000ml 18重量%的氢氧化钠溶液浸泡 60分钟;
(2) 把 (1 ) 中得到的纤维取出并挤干, 然后浸泡在预热至 41°C的醚 化液中 (氯乙酸钠 1000g, 30 重量%的氢氧化钠 830g, 乙醇 2000g, 纯水 2000g) , 控制醚化液的温度在 50-55°C并使其充分反应 60分钟;
(3 ) 取出 (2 ) 中得到的纤维, 使其在酸性洗涤液 (乙醇 500ml, 纯水 300ml, 醋酸 200ml)中浸泡 30分钟,然后重复在该酸性洗涤液中泡洗 2次, 直至其显中性或偏酸性;
(4) 把 (3 ) 中得到的纤维取出并挤干, 然后放入吐温 20含量为 2重 量%的 1000ml的乙醇溶液中充分浸泡洗涤、 上油;
(5 ) 把(4) 中得到的纤维取出并挤干, 然后 40°C下风干 50min, 得到 改性海丝纤维。
上述方法得到的改性海丝纤维的取代度是 0.29。
切断所得到的改性的海丝纤维并得到线密度为 3dtex,纤维长度为 50mm 的短纤, 然后用常规的无纺布线制得改性海丝纤维无纺布; 再经过分割、 切 断、包装和灭菌制成一定规格的改性海丝纤维伤口敷料。 此种伤口敷料的吸 收量为 19g/100cm2, 湿强度为 0.35N/cm。 实施例 2
( 1 ) 在室温下, 将 100g购自 smartfiber的商标名为 seacel的海丝纤维 用 600ml25重量%的氢氧化钠溶液浸泡 50分钟;
(2 ) 把 (1 ) 中得到的纤维取出并挤干, 然后浸泡在预热至 38°C的醚 化液中 (氯乙酸钠 1000g, 30重量。 /。的氢氧化钠 1630g, 乙醇 2500g, 纯水 1450g) , 控制醚化液的温度在 55-60°C并使其充分反应 60分钟;
(3 ) 取出 (2 ) 中得到的纤维, 使其在酸性洗涤液 (乙醇 500ml, 纯水 300ml, 醋酸 200ml)中浸泡 30分钟,然后重复在该酸性洗涤液中泡洗 2次, 直至其显中性或偏酸性;
(4) 把 (3 ) 中得到的纤维取出并挤干, 然后放入吐温 20 含量为 1.5
重量%的 600ml的乙醇溶液中充分浸泡洗涤、 上油;
( 5 ) 把(4) 中得到的纤维取出并挤干, 然后 40°C下风干 50min, 得到 改性海丝纤维。
上述方法得到的改性海丝纤维的取代度是 0.28。
切断所得到的改性海丝纤维并得到线密度为 4dtex, 纤维长度为 60mm 的短纤, 然后用常规的无纺布线制得改性海丝纤维无纺布; 再经过分割、 切 断、包装和灭菌后制成一定规格的改性海丝纤维伤口敷料。 此种伤口敷料的 吸收量为 19.5g/100cm2, 湿强度为 0.40N/cm。 实施例 3
( 1 ) 在室温下, 将 100g购自 smartfiber的商标名为 seacel的海丝纤维 用 600ml25重量%的氢氧化钠溶液浸泡 50分钟;
(2 ) 把 (1 ) 中得到的纤维取出并挤干, 然后浸泡在预热至 43°C的醚 化液中 (氯乙酸钠 1000g, 30重量。 /。的氢氧化钠 2500g, 乙醇 2500g, 纯水 1750g) , 控制醚化液的温度在 55-60°C并使其充分反应 46分钟;
(3 ) 取出 (2 ) 中得到的纤维, 使其在酸性洗涤液 (乙醇 500ml, 纯水 300ml, 醋酸 200ml)中浸泡 60分钟,然后重复在该酸性洗涤液中泡洗 2次, 直至其显中性或偏酸性;
(4) 把 (3 ) 中得到的纤维取出并挤干, 然后放入吐温 20 含量为 1.5 重量%的 600ml的乙醇溶液中充分浸泡洗涤、 上油;
( 5 ) 把(4) 中得到的纤维取出并挤干, 然后 40°C下风干 50min, 得到 改性海丝纤维。
上述方法得到的改性海丝纤维的取代度是 0.30。
切断所得到的改性海丝纤维并得到线密度为 5dtex, 纤维长度为 55mm 的短纤, 然后用常规的无紡布线制得改性海丝纤维无纺布; 再经过分割、 切 断、包装和灭菌后制成一定规格的改性海丝纤维伤口敷料。 此种伤口敷料的 吸收量为 21g/100cm2, 湿强度为 0.35N/cm。 实施例 4
通过实施例 1 的方法获得的线密度为 4dtex, 长度为 55mm的改性海丝 纤维短纤与佛山市优特医疗科技有限公司开发的改性纤维素进行混紡, 经过
开松、 梳理、 铺网和两次针刺后制得无纺布, 然后经过分割、 切断、 包装和 灭菌后制成一定规格的伤口敷料, 此种伤口敷料的吸收量为 19g/100cm2, 湿 强度为 0.38N/cm。 实施例 5
通过实施例 1的方法获得的线密度为 4dtex, 长度为 55mm的改性海丝 纤维短纤与购自即发集团的酰化壳聚糖纤维进行混纺, 经过开松、 梳理、 铺 网和两次针刺后制得无纺布, 然后经过分割、 切断、 包装和灭菌后制成一定 规格的伤口敷料,此种伤口敷料的吸收量为 15g/100cm2,湿强度为 0.50N/cm。 实施例 6
通过实施例 2的方法获得的线密度为 3dtex, 长度为 55mm的改性海丝 纤维短纤与佛山市优特医疗科技有限公司开发的 M型海藻酸纤维进行混纺, 经过开松、 梳理、 铺网和两次针刺后制得无纺布, 然后经过分割、 切断、 包 装和灭菌后制成一定规格的伤口敷料, 此种伤口敷料的吸收量为 14g/100cm2, 湿强度为 1.30N/cm。 实施例 Ί
通过实施例 2的方法获得的线密度为 3dtex, 长度为 55mm的改性海丝 纤维短纤与佛山市优特医疗科技有限公司开发的 M/G型海藻酸纤维进行混 纺, 经过开松、梳理、铺网和两次针刺后制得无纺布, 然后经过分割、切断、 包装和灭菌后制成一定规格的伤口敷料, 此种伤口敷料的吸收量为 16g/100cm2, 湿强度为 1.60N/cm。 实施例 8
通过实施例 1的方法获得的线密度为 4dtex, 长度为 55mm的改性海丝 纤维短纤、佛山市优特医疗科技有限公司开发的改性纤维素纤维和购自即发 集团的酰化壳聚糖纤维进行混纺, 经过开松、 梳理、 铺网和两次针刺后制得 无纺布, 然后经过分割、 切断、 包装和灭菌后制成一定规格的伤口敷料, 此 种伤口敷料的吸收量为 21g/100cm2, 湿强度为 0.85N/cm。
实施例 9
制备含银改性海丝纤维:
( 1 ) 准确称取 30g通过实施例 2的方法获得的改性海丝纤维;
(2) 配制 300ml的硝酸银的水 /乙醇溶液, 其中乙醇占 5%、 硝酸银为 lg, 使硝酸银充分溶解在水 /乙醇溶液中;
(3 ) 预热 (2 ) 中的硝酸银溶液至 40。C, 然后加入改性海丝纤维并浸 泡 5分钟;
(4)按与硝酸银摩尔比为 1 : 1的关系加入氯化钠,使硝酸银转变成氯化 银并沉积在纤维表面;
( 5 ) 烘干后避光保存, 得到含银改性海丝纤维。
上述方法制得的含银改性海丝纤维的含银量为 1.2%。 实施例 10
制备含银改性海丝纤维:
( 1 ) 准确称取 30g通过实施例 2的方法获得的改性海丝纤维;
(2) 配制 300ml的硝酸银的水 /乙醇溶液, 其中乙醇占 5%、 硝酸银为 lg, 使硝酸银充分溶解在水 /乙醇溶液中;
(3 ) 预热 (2 ) 中的硝酸银溶液至 40。C, 然后加入改性海丝纤维并浸 泡 5分钟;
(4)按与硝酸银摩尔比为 1 : 1的关系加入次氯酸钠,使硝酸银转变成氯 化银并沉积在纤维表面;
( 5 ) 烘干后避光保存, 得到含银改性海丝纤维。
上述方法制得的含银改性海丝纤维的含银量为 1.0%。 实施例 11
通过实施例 10的方法获得的线密度为 2dtex,长度为 55mm的含银改性 海丝纤维短纤与佛山市优特医疗科技有限公司开发的 M/G型海藻酸纤维进 行混纺, 经过开松、 梳理、 铺网和两次针剌后制得无纺布, 然后经过分割、 切断、 包装和灭菌后制成一定规格的伤口敷料, 此种伤口敷料的吸收量为 14g/100cm2, 湿强度为 1.45N/cm。
实施例 12
通过实施例 10的方法获得的线密度为 2dtex,长度为 60mm的含银改性 海丝纤维短纤与购自即发集团的含银酰化壳聚糖纤维进行混纺, 经过开松、 梳理、 铺网和两次针剌后制得无纺布, 然后经过分割、 切断、 包装和灭菌后 制成一定规格的伤口敷料, 此种伤口敷料的吸收量为 17g/100cm2, 湿强度为 1.0N/cm。
Claims
1、 一种化学改性的海丝纤维, 其特征在于, 所述海丝纤维中的纤 维素成分经过化学改性引入吸水性基团而转变成改性纤维素成分, 所 述改性纤维素成分的取代度为 0.05-0.5, 优选 0.2-0.4, 所述海丝纤维的 线密度是 0.5-5dtex, 优选 l-4dtex , 纤维长度是 5-180mm, 优选 15-125mm。
2、 根据权利要求 1所述的化学改性的海丝纤维, 其特征在于, 所 述海丝纤维是通过在纤维素纺丝液中加入海藻颗粒, 然后经过干湿法 纺丝或溶剂纺丝制备而成。
3、 根据权利要求 2所述的化学改性的海丝纤维, 其特征在于, 所 述海藻颗粒的粒径是 1-100μηι, 优选 1-50μηι。
4、 根据权利要求 2所述的化学改性的海丝纤维, 其特征在于, 所 述海藻颗粒选自红藻颗粒、 褐藻颗粒和棕藻颗粒。
5、 根据权利要求 2所述的化学改性的海丝纤维, 其特征在于, 所 述海藻颗粒均匀且稳定地分布于所述改性纤维素成分的结构中。
6、 根据权利要求 1所述的化学改性的海丝纤维, 其特征在于, 所 述改性纤维素成分选自羧甲基纤维素纤维或羧乙基纤维素纤维。
7、 根据权利要求 2所述的化学改性的海丝纤维, 其特征在于, 所 述改性纤维素成分吸收渗出液后形成湿润的凝胶, 使得所述海藻颗粒 的活性成分缓慢地释出, 从而为伤口提供湿润和营养的愈合环境。
8、 根据权利要求 7所述的化学改性的海丝纤维, 其特征在于, 所 述海藻颗粒的活性成分选自海藻酸、 碳水化合物、 氨基酸、 矿物质、 脂肪和维生素。
9、 根据权利要求 8所述的化学改性的海丝纤维, 其特征在于, 所 述海藻酸选自高甘露糖醛酸型或高古洛糖醛酸型或甘露糖醛酸 /古洛糖 醛酸混合型。
10、 一种由根据权利要求 1至 9中任一项所述的化学改性的海丝 纤维制备的伤口敷料, 其特征在于, 所述伤口敷料选自全部由所述化 学改性的海丝纤维制备的伤口敷料或由所述化学改性的海丝纤维与其 他纤维混纺制备的伤口敷料。
11、 根据权利要求 10所述的伤口敷料, 其特征在于, 所述伤口敷 料对 A溶液的吸收量达到 12g/100cm2以上。
12、 根据权利要求 10所述的伤口敷料, 其特征在于, 所述伤口敷 料的湿强度达到 0.3N/cm以上。
13、 根据权利要求 10所述的伤口敷料, 其特征在于, 所述其他纤 维选自海丝纤维、 纤维素纤维、 改性纤维素纤维优选羧甲基纤维素纤 维或羧乙基纤维素纤维、 海藻酸盐纤维优选海藻酸钙纤维或海藻酸钙 钠纤维、 壳聚糖纤维、 改性壳聚糖纤维优选酰化壳聚糖纤维或羧甲基 壳聚糖纤维、 莱赛尔纤维、 黏胶纤维、 锦纶纤维、 维纶纤维和涤纶纤 维。
14、 根据权利要求 10所述的伤口敷料, 其特征在于 , 所述伤口敷 料还含有抗菌剂, 例如银盐、 纳米银和聚六亚甲基双胍。
15、 根据权利要求 10所述的伤口敷料, 其特征在于, 所述伤口敷 料通过机织、 针织或非织造工艺制备。
16、 一种制备根据权利要求 1至 9中任一项所述的化学改性的海 丝纤维的方法, 其特征在于, 包括如下步骤:
1 ) 在室温下在 10重量%-50重量%的氢氧化钠溶液中充分浸泡和 打散海丝纤维, 其中所述海丝纤维和所述氢氧化钠溶液的体积比为 1 :7
至 1: 10;
2 ) 把 1 ) 中得到的纤维取出并挤干, 然后与醚化液进行醚化反应 10-120 分钟, 所述醚化液为由氯乙酸钠、 氢氧化钠、 水和乙醇组成的 溶液, 其中氯乙酸钠的浓度以醚化液的总重量计为 18-50重量。 /。;
3 ) 取出 2 ) 中得到的纤维并使用酸性洗涤液洗涤两次, 然后使用 浓度为 0.1-5重量%的吐温 20的无水乙醇溶液洗涤, 所述酸性洗涤液 包含以酸性洗涤液总重量计 0.5-5 重量%的醋酸, 20-60重量%的水和 35-79.5 重量%的乙醇, 且所述酸性洗涤液与所述纤维的质量比为 5:1 至 50: 1 ;
4) 将 3 ) 中得到的纤维在 30-80°C的温度下风干 10-60分钟, 得 到化学改性的海丝纤维。
17、 根据权利要求 16所述的方法, 其特征在于, 所述步骤 2 ) 中 的醚化反应如下进行: 先把所述醚化液预热至 30-50°C, 然后加入歩骤 1 ) 中得到的纤维并加热, 待所述醚化液的温度达到 40-65°C时开始循 环冷却, 使所述醚化液的温度维持在 45-60°C直至纤维成胶。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/655,849 US10603218B2 (en) | 2012-12-28 | 2013-09-02 | Chemically modified seacell fibres, wound dressing made therefrom and preparation method thereof |
EP13869833.7A EP2940198A4 (en) | 2012-12-28 | 2013-09-02 | CHEMICALLY MODIFIED BYSSUS FIBER, DRESSING MADE THEREFROM, AND PROCESS FOR PREPARING THE SAME |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210586749.X | 2012-12-28 | ||
CN201210586749XA CN103074699A (zh) | 2012-12-28 | 2012-12-28 | 化学改性的海丝纤维、由其制成的伤口敷料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014101458A1 true WO2014101458A1 (zh) | 2014-07-03 |
Family
ID=48151391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/082802 WO2014101458A1 (zh) | 2012-12-28 | 2013-09-02 | 化学改性的海丝纤维、由其制成的伤口敷料及其制备方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10603218B2 (zh) |
EP (1) | EP2940198A4 (zh) |
CN (1) | CN103074699A (zh) |
WO (1) | WO2014101458A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113398314A (zh) * | 2021-06-11 | 2021-09-17 | 长春工业大学 | 一种手持静电纺丝单向导液伤口敷料的制备方法 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103074699A (zh) * | 2012-12-28 | 2013-05-01 | 佛山市优特医疗科技有限公司 | 化学改性的海丝纤维、由其制成的伤口敷料及其制备方法 |
CN104562293B (zh) * | 2013-10-22 | 2017-05-17 | 成立萍 | 一种锁水性壳聚糖纤维的制备方法 |
CN103736138A (zh) * | 2013-12-22 | 2014-04-23 | 褚加冕 | 一种载银海藻酸钙医用敷料的制备方法 |
KR20160142389A (ko) * | 2014-04-08 | 2016-12-12 | 스마트폴리머 게엠베하 | 내부에 생리 활성 미네랄 물질이 분산되어 있는 셀룰로스 성형체 |
GB201420862D0 (en) * | 2014-11-24 | 2015-01-07 | Mouton Jacobus F | Wound dressing |
GB2554651B (en) * | 2016-09-30 | 2019-08-28 | Adv Med Solutions Ltd | Nonwoven Fabric Comprising Gelling Fibres |
CN106421875B (zh) * | 2016-11-15 | 2019-08-27 | 广州迈普再生医学科技股份有限公司 | 可降解吸收的止血纤维材料及其制备方法和止血纤维制品 |
EP3660191B1 (en) | 2017-07-25 | 2022-04-27 | Huizhou Foryou Medical Devices Co., Ltd. | Antimicrobial alginate fibre, and preparation method for and use of dressing thereof |
CN112575583A (zh) * | 2020-12-01 | 2021-03-30 | 四川大学 | 一种聚合胍接枝改性的耐久安全抗菌棉织物及其整理方法 |
CN112679628B (zh) * | 2020-12-24 | 2021-10-26 | 张家口健垣精准医学有限公司 | 基于海藻纤维的医用敷料及其制备方法 |
CN114276051B (zh) * | 2021-12-22 | 2023-01-17 | 苏州东振路桥工程有限公司 | 路面修复用抗裂冷拌沥青及其制备方法 |
CN114108118A (zh) * | 2021-12-30 | 2022-03-01 | 罗莱生活科技股份有限公司 | 一种莱赛尔纤维及其制备方法 |
CN114904041B (zh) * | 2022-05-31 | 2023-02-28 | 山东大学 | 一种基于地锦草提取物的医用敷料及其制备方法 |
CN115192759B (zh) * | 2022-07-26 | 2023-11-24 | 中原工学院 | 基于毛细效应具有伤口湿度控制功能的生物基医用纤维材料及其制备方法 |
KR102632532B1 (ko) * | 2023-03-13 | 2024-02-05 | 박수지 | 해조류를 이용한 생분해성 원사의 제조방법 및 그 제조방법으로 제조된 생분해성 원사가 함유된 직물의 제조방법 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2790049B2 (ja) * | 1994-09-07 | 1998-08-27 | 日本電気株式会社 | 記録装置 |
CN1307489A (zh) * | 1998-07-01 | 2001-08-08 | 厄苛迪斯特制纤维有限公司 | 绷带及其制备方法和合适使用的材料 |
CN101168869A (zh) | 2007-11-08 | 2008-04-30 | 山东海龙股份有限公司 | 大豆蛋白/海藻酸盐/纤维素纤维及其制备方法 |
CN101613893A (zh) | 2009-07-29 | 2009-12-30 | 武汉科技学院 | 细菌纤维素/海藻酸钠复合纤维及其制备方法 |
CN101967698A (zh) | 2010-10-02 | 2011-02-09 | 山东海龙股份有限公司 | 一种海藻酸盐/纤维素复合纤维的制备方法 |
CN102580136A (zh) * | 2011-01-07 | 2012-07-18 | 佛山市优特医疗科技有限公司 | 高吸湿且整片去除的伤口敷料 |
CN103074699A (zh) * | 2012-12-28 | 2013-05-01 | 佛山市优特医疗科技有限公司 | 化学改性的海丝纤维、由其制成的伤口敷料及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016746A1 (en) * | 1993-01-22 | 1994-08-04 | Courtaulds Plc | Wound dressings |
JP3901215B2 (ja) * | 1994-09-29 | 2007-04-04 | アドバンスド メディカル ソリューションズ リミテッド | 繊維 |
EP1607078A3 (en) * | 2000-07-18 | 2006-03-22 | Coloplast A/S | A dressing |
GB2370226A (en) * | 2000-09-21 | 2002-06-26 | Acordis Speciality Fibres Ltd | Wound dressing |
GB0026863D0 (en) * | 2000-11-03 | 2000-12-20 | Ssl Int Plc | Polysaccharide fibres |
DE10140772A1 (de) * | 2001-08-20 | 2003-03-13 | Zimmer Ag | Verfahren zur Entfernung von Schwermetallen aus schwermetallhaltigen Medien unter Verwendung eines Lyocell-Formkörpers sowie Lyocell-Formkörper mit adsorbierten Schwermetallen und deren Verwendung |
US6809231B2 (en) * | 2001-11-21 | 2004-10-26 | The United States Of America As Represented By The Secretary Of Agriculture | Flexible and absorbent alginate wound dressing |
CN100415960C (zh) * | 2006-05-29 | 2008-09-03 | 山东海龙股份有限公司 | 纤维素/海藻酸盐复合纤维及其制备方法 |
GB0623473D0 (en) * | 2006-11-24 | 2007-01-03 | Bristol Myers Squibb Co | Dissolution and processing of cellulose |
CN100558950C (zh) * | 2007-06-16 | 2009-11-11 | 山东海龙股份有限公司 | 生物活性海藻粘胶纤维及其制造方法 |
US9221963B2 (en) * | 2008-11-27 | 2015-12-29 | Speciality Fibres And Materials Ltd. | Absorbent material |
-
2012
- 2012-12-28 CN CN201210586749XA patent/CN103074699A/zh active Pending
-
2013
- 2013-09-02 EP EP13869833.7A patent/EP2940198A4/en not_active Withdrawn
- 2013-09-02 WO PCT/CN2013/082802 patent/WO2014101458A1/zh active Application Filing
- 2013-09-02 US US14/655,849 patent/US10603218B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2790049B2 (ja) * | 1994-09-07 | 1998-08-27 | 日本電気株式会社 | 記録装置 |
CN1307489A (zh) * | 1998-07-01 | 2001-08-08 | 厄苛迪斯特制纤维有限公司 | 绷带及其制备方法和合适使用的材料 |
CN101168869A (zh) | 2007-11-08 | 2008-04-30 | 山东海龙股份有限公司 | 大豆蛋白/海藻酸盐/纤维素纤维及其制备方法 |
CN101613893A (zh) | 2009-07-29 | 2009-12-30 | 武汉科技学院 | 细菌纤维素/海藻酸钠复合纤维及其制备方法 |
CN101967698A (zh) | 2010-10-02 | 2011-02-09 | 山东海龙股份有限公司 | 一种海藻酸盐/纤维素复合纤维的制备方法 |
CN102580136A (zh) * | 2011-01-07 | 2012-07-18 | 佛山市优特医疗科技有限公司 | 高吸湿且整片去除的伤口敷料 |
CN103074699A (zh) * | 2012-12-28 | 2013-05-01 | 佛山市优特医疗科技有限公司 | 化学改性的海丝纤维、由其制成的伤口敷料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
QIN, YIMIN: "Carboxymethyl cellulose fibers used for wound dressings", JOURNAL OF TEXTILE RESEARCH, vol. 27, no. 7, 15 July 2006 (2006-07-15), pages 97 - 99, XP008180059 * |
QIN, YIMIN: "Production method of Seacell fibers", JOURNAL OF TEXTILE RESEARCH, vol. 28, no. 10, 15 October 2007 (2007-10-15), pages 122, 123,130, XP008180060 * |
See also references of EP2940198A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113398314A (zh) * | 2021-06-11 | 2021-09-17 | 长春工业大学 | 一种手持静电纺丝单向导液伤口敷料的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2940198A1 (en) | 2015-11-04 |
US20150335492A1 (en) | 2015-11-26 |
US10603218B2 (en) | 2020-03-31 |
CN103074699A (zh) | 2013-05-01 |
EP2940198A4 (en) | 2016-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014101458A1 (zh) | 化学改性的海丝纤维、由其制成的伤口敷料及其制备方法 | |
JP4499669B2 (ja) | 外傷包帯 | |
FI115608B (fi) | Haavakääre | |
CN107376000B (zh) | 微纤维态止血材料及其制备方法和止血制品 | |
WO2014044011A1 (zh) | 海藻酸盐机织布及其制备方法 | |
CN103161028A (zh) | 含羧甲基纤维素纤维的无纺布及其用于美容面膜基材中的用途 | |
CN106894111A (zh) | 一种柔软吸湿的复合藻酸盐敷料的制备方法 | |
WO1994016746A1 (en) | Wound dressings | |
CN106421875B (zh) | 可降解吸收的止血纤维材料及其制备方法和止血纤维制品 | |
WO2012142879A1 (zh) | 具有抑菌性和吸湿性的伤口敷料 | |
CN107115555A (zh) | 一种高效吸液止血的复合型敷料及其制备方法 | |
US8389498B2 (en) | Spinning solution and method for manufacturing biomaterial fibers | |
CN103012859B (zh) | 甲壳胺和藻酸丙二醇酯共混材料及其制备方法和应用 | |
US4041121A (en) | Method for making high fluid-holding fiber mass | |
CN107115554A (zh) | 一种高效止血祛痛的复合型敷料及其制备方法 | |
CN103174017B (zh) | 一种氧化海藻酸钠改性的甲壳胺纤维及其制备方法和应用 | |
JP2013204205A (ja) | 消臭性再生セルロース繊維、その製造方法及び繊維構造物 | |
CN1030339C (zh) | 可吸收止血敷料的制法 | |
CN1034351C (zh) | 甲壳质纤维的制造方法 | |
RU2807862C1 (ru) | Гемостатическое средство на основе хитозана | |
CN113123130B (zh) | 一种纤维材料及其制备方法和应用 | |
RU2806364C1 (ru) | Способ получения гемостатического средства на основе хитозана | |
TWI400075B (zh) | 紡絲原液及製造生醫纖維方法 | |
TWM644049U (zh) | 吸濕抗菌功能性纖維 | |
CN116834385A (zh) | 一种复凝甲壳素纤维抗菌抑菌复合无纺布及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13869833 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14655849 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013869833 Country of ref document: EP |